From: Persistence of Candida dubliniensis and lung function in patients with cystic fibrosis
Parameters | ≤18 years (N = 18) | >18 years (N = 11) | P |
---|---|---|---|
N(%) | N(%) | ||
Sex/male | 10 (55.6) | 7 (63.6) | 0.668 |
No. of CF patients with CFTR 1234 V mutation | 18 (100) | 11 (100) | |
No. of CF patients with pancreatic sufficiency | 18 (100) | 10 (90.9) | 0.193 |
No. of CF patients with CF related diabetes | 0 (0) | 4 (36.4) | 0.014 |
Nebulized Tobramycin use | 7 (38.9) | 8 (72.7) | 0.077 |
Oral zythromax use | 0 (0) | 6 (54.5) | 0.001 |
Nebulized pulmozyme use | 12 (66.7) | 10 (90.9) | 0.139 |
Nebulized hypertonic saline use | 5 (27.8) | 6 (54.5) | 0.149 |